Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.)

Scopus

Scopus profile and journal metrics

This journal is indexed in Scopus. Use these metrics for a quick publishing snapshot, then open the Scopus page for the authoritative profile.

Scopus
Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.) Indexed in Scopus since 2022
CiteScore 1.0
Indexed since 2022
First decision 7 Days
Submission to acceptance 45 Days
Acceptance to publication 14 Days
Acceptance rate 8%

SCImago

SCImago Journal Rank preview

Use SCImago when you want a quick visual view of the journal ranking profile and external discoverability signals.

Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.) SCImago Journal & Country Rank

DOAJ

Directory of Open Access Journals listing

The DOAJ record is useful for readers, librarians, and authors who want a direct open-access directory entry for the journal.

DOAJ
Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.) Open directory record
Original full research article

Reappraisal of nonsteroidal anti-inflammatory drugs̕ effects on kidney outcomes

Published
2022-05-23
Pages
207 - 216
Full text

Keywords

  • Kidney
  • factors
  • Risk
  • Acute
  • injury;
  • anti-inflammatory
  • Nonsteroidal
  • Diclofenac
  • drugs;
  • Sodium;

Abstract

Introduction: Nonsteroidal anti-inflammatory drugs are the most common drugs as a prescription or over-the-counter drugs, and acute kidney injury (AKI) is one of the dangerous complications of these drugs. This research aims to assess the risk and effect of nonsteroidal anti-inflammatory drugs on kidney outcomes. Methods: In the prospective analytic (experi-mental) study type with randomized clinical trial design and article type of systematic review and meta-analysis, 32 patients with nonsteroidal anti-inflammatory drug-induced nephropa-thy were enrolled. The prevalence of complications, relative risk, and odds ratio as effective measures of endpoints were assessed in the present research. Results: Of 32 patients in non-steroidal anti-inflammatory induced nephropathy, 16 patients (16/32, 50%) were male, and sixteen patients (16/32, 50%) were women. AKI was the most common complication of these drugs (14/32, 43.7%), and the prevalence of diclofenac sodium was 34.3% (11/32) as the most common drug in the induction of nonsteroidal anti-inflammatory drugs nephropathy. Relative risk and odds ratio of AKI in patients with nonsteroidal anti-inflammatory induced nephropathy were evaluated at 0.94 with 95% confidence level of 0.09803 to 6.247 and 0.75 with 95% CI of 0.06368 to 8.8339, respectively. Conclusion: Nonsteroidal anti-inflammatory drugs were accompanied by low risk and Odds ratio of AKI in the present investigation. In the present research, diclofenac sodium was reported as the most common drug in nonsteroi-dal anti-inflammatory-induced nephropathy.

Article history

Received
2021-08-26
Accepted
2022-05-23
بحث أصيل كامل

Reappraisal of nonsteroidal anti-inflammatory drugs̕ effects on kidney outcomes

Published
2022-05-23
الصفحات
207 - 216
البحث كاملا

الكلمات الإفتتاحية

  • Kidney
  • factors
  • Risk
  • Acute
  • injury;
  • anti-inflammatory
  • Nonsteroidal
  • Diclofenac
  • drugs;
  • Sodium;

الملخص

Introduction: Nonsteroidal anti-inflammatory drugs are the most common drugs as a prescription or over-the-counter drugs, and acute kidney injury (AKI) is one of the dangerous complications of these drugs. This research aims to assess the risk and effect of nonsteroidal anti-inflammatory drugs on kidney outcomes. Methods: In the prospective analytic (experi-mental) study type with randomized clinical trial design and article type of systematic review and meta-analysis, 32 patients with nonsteroidal anti-inflammatory drug-induced nephropa-thy were enrolled. The prevalence of complications, relative risk, and odds ratio as effective measures of endpoints were assessed in the present research. Results: Of 32 patients in non-steroidal anti-inflammatory induced nephropathy, 16 patients (16/32, 50%) were male, and sixteen patients (16/32, 50%) were women. AKI was the most common complication of these drugs (14/32, 43.7%), and the prevalence of diclofenac sodium was 34.3% (11/32) as the most common drug in the induction of nonsteroidal anti-inflammatory drugs nephropathy. Relative risk and odds ratio of AKI in patients with nonsteroidal anti-inflammatory induced nephropathy were evaluated at 0.94 with 95% confidence level of 0.09803 to 6.247 and 0.75 with 95% CI of 0.06368 to 8.8339, respectively. Conclusion: Nonsteroidal anti-inflammatory drugs were accompanied by low risk and Odds ratio of AKI in the present investigation. In the present research, diclofenac sodium was reported as the most common drug in nonsteroi-dal anti-inflammatory-induced nephropathy.

Article history

تاريخ التسليم
2021-08-26
تاريخ القبول
2022-05-23